Zolbetuximab Could Alter Frontline Treatment Paradigm for CLDN18.2+ Gastric/GEJ Cancer
Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.